The potential effect of statins on rituximab immunotherapy.

Código QR

The potential effect of statins on rituximab immunotherapy.

Guardado en:

Detalles Bibliográficos
Autor principal:	Mark S Cragg
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2008
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/a6ee79dcc5fd475c8567d92d415067f7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
por: Magdalena Winiarska, et al.
Publicado: (2008)

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk E, et al.
Publicado: (2012)

Pleiotropic effects of statins: New evidences
por: Kaan Okyay
Publicado: (2021)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Haralampos M Moutsopoulos, et al.
Publicado: (2008)

Safety of switching between rituximab biosimilars in onco-hematology
por: Silvana A. M. Urru, et al.
Publicado: (2021)

Rituximab in the treatment of non-Hodgkin&rsquo;s lymphoma
por: Beate Hauptrock, et al.
Publicado: (2008)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
por: Joseph M Tuscano, et al.
Publicado: (2009)

Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous
por: Yashavanthi Mysore, et al.
Publicado: (2021)

Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers
por: Mahshid Ataei, et al.
Publicado: (2021)

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
por: Nancy L Monson, et al.
Publicado: (2011)

Author Correction: Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous
por: Yashavanthi Mysore, et al.
Publicado: (2021)

Eosinophilic esophagitis: A potential complication of sublingual immunotherapy
por: Knežević Snežana B., et al.
Publicado: (2021)

PREVENTIVE EFFECT OF LONG ACTING Β2-AGONISTS ON STATIN INDUCED MYOPATHIES
por: Abdullah Qamar, et al.
Publicado: (2018)

Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer.
por: Ide T Spaanderman, et al.
Publicado: (2021)

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.
por: Mariam Molokhia, et al.
Publicado: (2008)

Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome
por: Jihaeng Im, et al.
Publicado: (2021)

Rituximab for refractory granulomatous eye disease
por: Lower EE, et al.
Publicado: (2012)

Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy
por: Yang-Hong Dai, et al.
Publicado: (2021)

Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
por: Hasan E, et al.
Publicado: (2012)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song L, et al.
Publicado: (2019)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Margarida Gaudencio, et al.
Publicado: (2021)

The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials.
por: Laura Pasin, et al.
Publicado: (2013)

Are statins beneficial for the treatment of pulmonary hypertension?
por: Lei Wang, et al.
Publicado: (2017)

The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials
por: Mateusz Socha, et al.
Publicado: (2019)

Vesiculobullous disease with Cutaneous Systemic Lupus Erythematosus Treated by Rituximab: A case report
por: Wigdan Mohammed Niamat Alla, et al.
Publicado: (2021)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
por: Re KA, et al.
Publicado: (2012)

Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
por: Benucci M, et al.
Publicado: (2013)

Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks
por: Yu-Cheng Kao, et al.
Publicado: (2021)

Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
por: Saeed H., et al.
Publicado: (2020)

Statins and the risk of lung cancer: a meta-analysis.
por: Min Tan, et al.
Publicado: (2013)

Treating statin-intolerant patients
por: Pigna G, et al.
Publicado: (2011)

Update on the use of rituximab for intractable rheumatoid arthritis
por: R John Looney
Publicado: (2009)

The evaluation and optimal use of rituximab in lymphoid malignancies
por: Smolewski P, et al.
Publicado: (2012)

Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis
por: Alessandra Vultaggio, et al.
Publicado: (2021)

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
por: Suhel Gabriele Al Khayyat, et al.
Publicado: (2021)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
por: Lurati A, et al.
Publicado: (2013)

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation
por: Juhan Lee, et al.
Publicado: (2018)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF&alpha; blocker failure
por: Kekow J, et al.
Publicado: (2012)

Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins.
por: Issam Zineh, et al.
Publicado: (2008)

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
por: Elisenda Climent, et al.
Publicado: (2017)